|
1
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:2791–1955. 2013. View Article : Google Scholar
|
|
2
|
Bernt KM and Hunger SP: Current concepts
in pediatric Philadelphia chromosome-positive acute lymphoblastic
leukemia. Front Oncol. 4:542014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fielding AK: How I treat Philadelphia
chromosome-positive acute lymphoblastic leukemia. Blood.
116:3409–3417. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pui CH, Sandlund JT, Pei D, Campana D,
Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson
MM, et al: Improved outcome for children with acute lymphoblastic
leukemia: Results of total therapy study XIIIB at St Jude
children's research hospital. Blood. 104:2690–2696. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Druker BJ, Guilhot F, O'Brien SG, Gathmann
I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM,
Stone RM, et al: Five-year follow-up of patients receiving imatinib
for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee HJ, Thompson JE, Wang ES and Wetzler
M: Philadelphia chromosome-positive acute lymphoblastic leukemia:
Current treatment and future perspectives. Cancer. 117:1583–1594.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maecker HT, Todd SC and Levy S: The
tetraspanin superfamily: Molecular facilitators. FASEB J.
11:428–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hemler ME: Tetraspanin functions and
associated microdomains. Nat Rev Mol Cell Biol. 6:801–811. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang JC, Bégin LR, Bérubé NG, Chevalier S,
Aprikian AG, Gourdeau H and Chevrette M: Down-regulation of CD9
expression during prostate carcinoma progression is associated with
CD9 mRNA modifications. Clin Cancer Res. 13:2354–2361. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zöller M: Tetraspanins: Push and pull in
suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peñas P, García-López M and del Río
Barreiro O: Inhibition of the motility of melanoma cells using
interference RNA against CD9. Actas Dermosifiliogr. 96:30–36.
2005.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herr MJ, Mabry SE, Jameson JF and Jennings
LK: Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is
regulated by epidermal growth factor receptor. Biochem Biophys Res
Commun. 442:99–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang GP and Han XF: CD9 modulates
proliferation of human glioblastoma cells via epidermal growth
factor receptor signaling. Mol Med Rep. 12:1381–1386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rappa G, Green TM, Karbanová J, Corbeil D
and Lorico A: Tetraspanin CD9 determines invasiveness and
tumorigenicity of human breast cancer cells. Oncotarget.
6:7970–7991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang M, Yin G, Wang F, Liu H, Zhou S, Ni
J, Chen C, Zhou Y and Zhao Y: Downregulation of CD9 promotes
pancreatic cancer growth and metastasis through upregulation of
epidermal growth factor on the cell surface. Oncol Rep. 34:350–358.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishida H, Yamazaki H, Yamada T, Iwata S,
Dang NH, Inukai T, Sugita K, Ikeda Y and Morimoto C: CD9 correlates
with cancer stem cell potentials in human B-acute lymphoblastic
leukemia cells. Biochem Biophys Res Commun. 382:57–62. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamazaki H, Xu CW, Naito M, Nishida H,
Okamoto T, Ghani FI, Iwata S, Inukai T, Sugita K and Morimoto C:
Regulation of cancer stem cell properties by CD9 in human B-acute
lymphoblastic leukemia. Biochem Biophys Res Commun. 409:14–21.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arnaud MP, Vallée A, Robert G, Bonneau J,
Leroy C, Varin-Blank N, Rio AG, Troadec MB, Galibert MD and
Gandemer V: CD9, a key actor in the dissemination of lymphoblastic
leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
Blood. 126:1802–1812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang P, Miao M, Liu Z, Wang H, Jiang W,
Ma S, Li C and Hu R: CD9 expression indicates a poor outcome in
acute lymphoblastic leukemia. Cancer Biomark. 21:781–786. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu J, Liang B, Qian Y, Tang L, Xing C,
Zhuang Q, Shen Z, Jiang S, Yu K and Feng J: Down-regulation of CD19
expression inhibits proliferation, adhesion, migration and invasion
and promotes apoptosis and the efficacy of chemotherapeutic agents
and imatinib in SUP-B15 cells. Cell Biol Int. 42:1228–1239. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sanber KS, Knight SB, Stephen SL, Bailey
R, Escors D, Minshull J, Santilli G, Thrasher AJ, Collins MK and
Takeuchi Y: Construction of stable packaging cell lines for
clinical lentiviral vector production. Sci Rep. 5:90212015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klein G, Vellenga E, Fraaije MW, Kamps WA
and de Bont ES: The possible role of matrix metalloproteinase
(MMP)-2 and MMP-9 in cancer, eg acute leukemia. Crit Rev Oncol
Hematol. 50:87–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barrena S, Almeida J, Yunta M, López A,
Fernández-Mosteirín N, Giralt M, Romero M, Perdiguer L, Delgado M,
Orfao A and Lazo PA: Aberrant expression of tetraspanin molecules
in B-cell chronic lymphoproliferative disorders and its correlation
with normal B-cell maturation. Leukemia. 19:1376–1383. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen Y and White E: p53-dependent
apoptosis pathways. Adv Cancer Res. 82:55–84. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slee EA, Adrain C and Martin SJ: Serial
killers: Ordering caspase activation events in apoptosis. Cell
Death Differ. 6:1067–1074. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kato M and Manabe A: Treatment and biology
of pediatric acute lymphoblastic leukemia. Pediatr Int. 60:4–12.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gleissner B, Gökbuget N, Bartram CR,
Janssen B, Rieder H, Janssen JWG, Fonatsch C, Heyll A, Voliotis D,
Beck J, et al: Leading prognostic relevance of the BCR-ABL
translocation in adult acute B-lineage lymphoblastic leukemia: A
prospective study of the german multicenter trial group and
confirmed polymerase chain reaction analysis. Blood. 99:1536–1543.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barrangou R, Birmingham A, Wiemann S,
Beijersbergen RL, Hornung V and van Brabant Smith A: Advances in
CRISPR-Cas9 genome engineering: Lessons learned from RNA
interference. Nucleic Acids Res. 43:3407–3419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grimm D, Streetz KL, Jopling CL, Storm TA,
Pandey K, Davis CR, Marion P, Salazar F and Kay MA: Fatality in
mice due to oversaturation of cellular microRNA/short hairpin RNA
pathways. Nature. 441:537–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaelin WG Jr: Use and abuse of RNAi to
study mammalian gene function. Science. 337:421–422. 2012.
View Article : Google Scholar : PubMed/NCBI
|
